{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Objective Radiographic Response Rate. Response assessments were based on the longest diameter tumor measurements in accordance with Response Evaluation Criteria in Solid Tumors (RECIST).","groups":[{"description":"Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks","id":"OG000","title":"Experimental: Sunitinib Malate (SU011248) Treatment"}],"paramType":"NUMBER","populationDescription":"All participants assessable for response","reportingStatus":"POSTED","timeFrame":"From On Treatment to Off Study - average of 6 months","title":"Number of Participants With Overall Response (OR)","type":"PRIMARY","unitOfMeasure":"participants"}